Literature DB >> 11356952

Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

B Labrosse1, C Treboute, A Brelot, M Alizon.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) entry is triggered by the interaction of the gp120 envelope glycoprotein with a cellular chemokine receptor, either CCR5 or CXCR4. We have identified different mutations in human CXCR4 that prevent efficient infection by one HIV-1 strain (NDK) but not another (LAI) and sought to define these strain-dependent effects at the gp120 level. The lack of activity toward the NDK strain of the HHRH chimeric CXCR4 in which the second extracellular loop (ECL2) derived from the rat CXCR4 and of CXCR4 with mutations at an aspartic acid in ECL2 (D193A and D193R) was apparently due to the sequence of the third variable loop (V3) of gp120, more precisely, to its C-terminal part. Indeed, substitution of the LAI V3 loop or only its C-terminal part in the NDK gp 120 context was sufficient to restore usage of the HHRH, D193A, and D193R receptors. The same result was achieved upon mutation of a single lysine residue of the NDK V3 loop to alanine (K319A) but not to arginine (K319R). These results provide a strong case for a direct interaction between the gp120 V3 loop and the ECL2 domain of CXCR4. By contrast, V3 substitutions had no effect on the inability of NDK to infect cells via a mutant CXCR4 in which the amino-terminal extracellular domain (NT) is deleted. In experiments with a set of chimeric NDK-LAI gp120s, the V1/V2 region from LAI gp120 was both necessary and sufficient for usage of the NT-deleted CXCR4. Different variable domains of gp120 can therefore cooperate for a functional interaction with CXCR4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356952      PMCID: PMC114257          DOI: 10.1128/JVI.75.12.5457-5464.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4.

Authors:  S Ugolini; M Moulard; I Mondor; N Barois; D Demandolx; J Hoxie; A Brelot; M Alizon; J Davoust; Q J Sattentau
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

4.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Authors:  A Brelot; N Heveker; O Pleskoff; N Sol; M Alizon
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry.

Authors:  O Pleskoff; C Tréboute; A Brelot; N Heveker; M Seman; M Alizon
Journal:  Science       Date:  1997-06-20       Impact factor: 47.728

6.  Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.

Authors:  N Heveker; M Montes; L Germeroth; A Amara; A Trautmann; M Alizon; J Schneider-Mergener
Journal:  Curr Biol       Date:  1998-03-26       Impact factor: 10.834

7.  Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.

Authors:  M W Cho; M K Lee; M C Carney; J F Berson; R W Doms; M A Martin
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

9.  CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins.

Authors:  Z X Wang; J F Berson; T Y Zhang; Y H Cen; Y Sun; M Sharron; Z H Lu; S C Peiper
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

Review 10.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

View more
  31 in total

1.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Authors:  Guity Ghaffari; Daniel L Tuttle; Daniel Briggs; Brant R Burkhardt; Deepa Bhatt; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

Review 4.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

5.  Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization.

Authors:  Jesse Isaacman-Beck; Emilia A Hermann; Yanjie Yi; Sarah J Ratcliffe; Joseph Mulenga; Susan Allen; Eric Hunter; Cynthia A Derdeyn; Ronald G Collman
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

6.  Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.

Authors:  Sayamon Hongjaisee; Martine Braibant; Francis Barin; Nicole Ngo-Giang-Huong; Wasna Sirirungsi; Tanawan Samleerat
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-12       Impact factor: 2.205

7.  P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.

Authors:  Alexandra Y Soare; Hagerah S Malik; Natasha D Durham; Tracey L Freeman; Raymond Alvarez; Foramben Patel; Namita Satija; Chitra Upadhyay; Catarina E Hioe; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

8.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

9.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.

Authors:  Wei Huang; Jonathan Toma; Signe Fransen; Eric Stawiski; Jacqueline D Reeves; Jeannette M Whitcomb; Neil Parkin; Christos J Petropoulos
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.